CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter Trial (ASH 2023) - Nov 3, 2023 - Abstract #771; Pres time: Dec 11, 2023; 11:00 AM - 11:15 AM; Location: Room 6CF (San Diego Convention Center); P1/2 | "All subjects received pre-CD33CART lymphodepleting chemotherapy (LD) with fludarabine (75-120 mg/m2) and cyclophosphamide (900-1000 mg/m2). CD33CART manufacturing is feasible in children and AYAs with r/r AML with acceptable toxicity experienced in treated subjects. CD33CART expansion was best in subjects treated at DL4 (1 x 107/kg) with MRD negative CRs and transient myeloid aplasia occurring in 2 of 5 (40%) subjects evaluable for response (Table). Based on early clinical efficacy at DL4, enrollment continues in the phase 2 portion."
CAR T-Cell Therapy • Clinical • P1/2 data • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Obesity • Palliative care • Pediatrics
|
|
Nirali N. Shah, M.D.1; Sarah K Tasian, MD2; M. Eric Kohler, MD, PhD3; Emily M. Hsieh, MD4; Susanne H.C. Baumeister, MD5; Corinne Summers, MD6; Haneen Shalabi, DO7; Jessica A. Pollard, MD8; Bonnie Yates, NP9; Ruta Brazauskas, PhD10; Eric Ndifon11; Constance M. Yuan, MD, PhD12; Hao-Wei Wang, MD, PhD12; Hati K Kobusingye13; Kayla Christianson13; Allison A Weiss13; Erin Leckrone13; Bronwen E. Shaw, PhD, MRCP, FRCPath14; Jeffery J. Auletta, MD15; Hemalatha G. Rangarajan, MD16; John Roach17; Julie Blake18; Dennis Michiel19; Brian Bowser17; Sheryl Ruppel17; George Mitra20; Anthony Welch21; Jason Yovandich22; Rachelle Salomon21; Leslie Kean23; Katherine Tarlock, MD24; Michael A. Pulsipher, MD25; Michael R Verneris, MD26; Larisa Broglie, MD27; Terry J. Fry, MD28; Steven M. Devine, MD29; Richard Aplenc, MD, PhD30
|